Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Vyriad, Inc.
ISA Pharmaceuticals
ISA Pharmaceuticals
M.D. Anderson Cancer Center
Jules Bordet Institute
University of Miami
Oncovir, Inc.